Abstract: With new cfDNA NGS assays being able to detect variants from as little as 2-10ng DNA, assay validation to ensure sufficient accuracy has never been so critical. Reference materials that closely mimic real cfDNA samples are essential to support this effort. Here we present results from a comparative study into the production of cfDNA reference standards, assessing enzymatic fragmentation compared to fragmentation by sonication, and the benefit of including a size selection step.Summary: Liquid biopsies hold great promise to revolutionise the field of clinical oncology testing. cfDNA can be extracted from a routine patient blood sample and used to determine the genetic profile of a solid tumour located elsewhere within the body. This facilitates more informative disease management for the clinician, without the need for invasive surgery for the patient.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
BAT Molecular Imaging with SPECT-CT, PET-CT, PET-MRI and Fluorescence-PET: A Systematic Review of the Literature Data
Tarik Z Belhocine, MD., Ph.D *, Albert A Driedger, MD., Ph.D **, Jean-Luc Urbain, MD., Ph.D ***
Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon
Platinum™ SuperFi™ DNA Polymerase for the highest success in PCR
Rasa Sukackaitė, Martyna Simutytė, Skaistė Valinskytė, Laurynas Vanagas, Karolis Matjošaitis, Renata Rimšelienė, Remigijus Skirgaila.
DNA-free Platinum Taq DNA polymerase for reliable microbiome studies
Kęstutis Bargaila, Vytautas Budrys, Andrius Krasauskas, Dovilė Lisauskienė, Milda Romeikaitė, Sonata Jurėnaitė-Urbanavičienė,Ramunė Leipuvienė and Juozas Šiurkus
The Good, the Bad and the Ugly: Selective single cell isolation
Sandra Lubos1,2, Nils Körber1, Heide Marie Resch1, Iris Augustin2, Stefan Niehren1